Study to examine experimental drug in patients with pleural mesothelioma

9 May 2018 by under Research/Treatment

research test tubes 100x100 Study to examine experimental drug in patients with pleural mesotheliomaMemorial is conducting a study to determine if adding an investigational drug to standard-of-care chemotherapy is more effective at extending lifespan in patients with malignant pleural mesothelioma.

The randomized, double-blind, phase II/III study, called POLAIS2015-003, is recruiting patients with malignant pleural mesothelioma with low argininosuccinate synthetase I expression. Aginine is a nutrient that makes up proteins. Laboratory studies show that ADI-PEG 20 can break down arginine, which can destroy cancer cells. Researchers want to determine if combining this experimental drug with stand-of-care chemotherapies is better than chemotherapy alone.

Patients in the study will receive chemotherapy with premetrexed and cisplatin or carboplatin, and will be randomly assigned to receive ADI-PEG 20 or a placebo. The chemotherapy is given to patients intravenously while ADI-PEG 20 is administered by injection.

To be eligible for the study, patients must be at least 18 years of age and have malignant pleural mesothelioma that has not yet been treated with chemotherapy or immunotherapy. Patients who have had major surgery must wait at least four weeks before entry into the study. Participants must be physically well enough that they are fully ambulatory, capable of all self care, and able to carry out regular activities except physically strenuous ones. For more information, visit ClinicalTrials.gov.

Malignant pleural mesothelioma is a rare but deadly type of lung cancer that affects the lining of the lungs. It is caused by exposure to , a fibrous mineral found naturally in rock and soil. has been widely used in a variety of products including building materials and fire-resistant fabrics, and also has been found in talcum powders.

Source: Memorial Sloan Kettering Cancer Center

Comments are closed.